Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Tarantini

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Annals of Hematology|May 19, 2022
Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by 'Rete Ematologica Pugliese'G Mele, N Cascavilla, N Di Renzo, et al.
Leukemia Research|February 1, 2015
"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese"G Mele, A Melpignano, G Quarta, et al.
International Journal of Cardiology|May 1, 2013
Mid-term prognostic value of coronary artery disease in patients undergoing transcatheter aortic valve implantation: a meta-analysis of adjusted observational resultsF D'Ascenzo, F Conrotto, F Giordana, et al.
International Journal of Cardiology|January 7, 2022
Excimer laser technology in percutaneous coronary interventions: Cardiovascular laser society's position paperL Golino, G Caiazzo, P Calabrò, et al.
ESMO Open|January 8, 2025
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patientsE A Martino, S Palmieri, M Galli, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Annals of Hematology|May 19, 2022
Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by 'Rete Ematologica Pugliese'G Mele, N Cascavilla, N Di Renzo, et al.
Leukemia Research|February 1, 2015
"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese"G Mele, A Melpignano, G Quarta, et al.
International Journal of Cardiology|May 1, 2013
Mid-term prognostic value of coronary artery disease in patients undergoing transcatheter aortic valve implantation: a meta-analysis of adjusted observational resultsF D'Ascenzo, F Conrotto, F Giordana, et al.
International Journal of Cardiology|January 7, 2022
Excimer laser technology in percutaneous coronary interventions: Cardiovascular laser society's position paperL Golino, G Caiazzo, P Calabrò, et al.
ESMO Open|January 8, 2025
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patientsE A Martino, S Palmieri, M Galli, et al.
Pageof 3